1/11
09:26 pm
rvph
Reviva Pharmaceuticals Holdings (RVPH) Records 37% in 2026 So far [Yahoo! Finance]
Medium
Report
Reviva Pharmaceuticals Holdings (RVPH) Records 37% in 2026 So far [Yahoo! Finance]
1/8
08:00 am
rvph
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
Medium
Report
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
1/5
08:33 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $2.00 price target on the stock.
Medium
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $2.00 price target on the stock.
12/29
08:12 am
rvph
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum [Yahoo! Finance]
Medium
Report
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum [Yahoo! Finance]
12/29
08:00 am
rvph
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
High
Report
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
12/27
01:05 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at
Wall St
Medium
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at
Wall St
12/24
08:02 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
High
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
12/23
09:02 am
rvph
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia [Yahoo! Finance]
Medium
Report
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia [Yahoo! Finance]
12/23
08:42 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.
Medium
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.
12/23
08:00 am
rvph
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
High
Report
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
12/16
03:26 am
rvph
Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High [Seeking Alpha]
Low
Report
Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High [Seeking Alpha]
11/21
05:31 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Medium
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/19
08:47 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.
Medium
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.